Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PIV5-OspA Lyme disease vaccine
- Development stage
- Preclinical
- Lead developer
- CyanVac
- Modality
- Live Vector Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
CyanVac, in collaboration with Immuno Technologies, is developing an intranasal live viral vector vaccine for the prevention of Lyme disease. The vaccine utilizes a proprietary parainfluenza virus 5 (PIV5) platform to deliver and express the Outer Surface Protein A (OspA) antigen of *Borrelia burgdorferi*, the primary causative agent of Lyme disease. Administered intranasally, the vaccine is designed to elicit both mucosal and systemic immune responses. Preclinical data published in 2024 demonstrated that a single intranasal dose provides durable protection for at least 15 months in murine models against tick-borne infection, showing superior longevity of neutralizing antibody responses compared to traditional subcutaneous recombinant protein vaccines.
- Other names
- Intranasal PIV5-OspA vaccineCyanVac Lyme disease vaccine
02
Targets
OspA (Outer surface protein A)
Beyond the preview
Go deeper on PIV5-OspA Lyme disease vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PIV5-OspA Lyme disease vaccine.